Nader Hanna

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11978025/publications.pdf

Version: 2024-02-01

30	2,009	17 h-index	26
papers	citations		g-index
30	30	30	3033
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Incidence and Risk Factors of Venous Thromboembolism Following Hepatectomy for Colorectal Metastases: A Populationâ€Based Retrospective Cohort Study. World Journal of Surgery, 2022, 46, 180-188.	1.6	4
2	NO [•] /RUNX3/kynurenine metabolic signaling enhances disease aggressiveness in pancreatic cancer. International Journal of Cancer, 2020, 146, 3160-3169.	5.1	24
3	Adjuvant therapy for pancreatic body or tail adenocarcinoma: a study of the National Cancer Database. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591984243.	3.2	4
4	Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2017, 24, 2259-2265.	1.5	24
5	Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer. Oncotarget, 2016, 7, 52993-53004.	1.8	35
6	A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2. Cancer Research, 2016, 76, 3838-3850.	0.9	212
7	Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon Cancer. Oncologist, 2016, 21, 676-683.	3.7	7
8	Algorithm for Identifying Chemotherapy/Biological Regimens for Metastatic Colon Cancer in SEER-Medicare. Medical Care, 2015, 53, e58-e64.	2.4	32
9	Soft tissue sarcomas in the general and referral population: The University of Maryland Medical Center experience Journal of Clinical Oncology, 2015, 33, e21525-e21525.	1.6	О
10	Treatment duration and survival time: Does only the last line matter?. Journal of Clinical Oncology, 2015, 33, e17695-e17695.	1.6	0
11	Does the type of firstâ€line regimens influence the receipt of secondâ€line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patients. Cancer Medicine, 2014, 3, 124-133.	2.8	5
12	Cost-Effectiveness of Second-Line Chemotherapy/Biologics among Elderly Metastatic Colon Cancer Patients. Advances in Therapy, 2014, 31, 724-734.	2.9	6
13	Inhibiting CARD11 translation during BCR activation by targeting the elF4A RNA helicase. Blood, 2014, 124, 3758-3767.	1.4	22
14	The impact of comorbidity on costs and effects of second-line treatment among elderly metastatic colon cancer patients Journal of Clinical Oncology, 2014, 32, 536-536.	1.6	O
15	Integration of Metabolomics and Transcriptomics Revealed a Fatty Acid Network Exerting Growth Inhibitory Effects in Human Pancreatic Cancer. Clinical Cancer Research, 2013, 19, 4983-4993.	7.0	280
16	Neoadjuvant Chemoradiation for Distal Rectal Cancer: 5-Year Updated Results of a Randomized Phase 2 Study of Neoadjuvant Combined Modality Chemoradiation for Distal Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 86, 523-528.	0.8	48
17	Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery, 2013, 153, 779-786.	1.9	118
18	Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. International Journal of Cancer, 2013, 132, 785-794.	5.1	111

#	Article	IF	CITATIONS
19	Clinical and demographic characteristics associated with the receipt of chemotherapy treatment among 7951 elderly metastatic colon cancer patients. Cancer Medicine, 2013, 2, 907-915.	2.8	6
20	Use of biologics in addition to chemotherapy in the treatment of elderly Medicare patients with stage IV metastatic colon cancer Journal of Clinical Oncology, 2013, 31, e14602-e14602.	1.6	O
21	Impact of Venous Thromboembolism on Mortality of Elderly Medicare Patients with Stage III Colon Cancer. Oncologist, 2012, 17, 1191-1197.	3.7	16
22	EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. Gastrointestinal Endoscopy, 2012, 75, 332-338.	1.0	138
23	The remarkably distensible stomach: Case report highlighting the implications of gastric filling on radiation treatment planning for gastric lymphoma. Practical Radiation Oncology, 2012, 2, 265-269.	2.1	2
24	DPEP1 Inhibits Tumor Cell Invasiveness, Enhances Chemosensitivity and Predicts Clinical Outcome in Pancreatic Ductal Adenocarcinoma. PLoS ONE, 2012, 7, e31507.	2.5	189
25	Comparative and costâ€effectiveness of oxaliplatinâ€based or irinotecanâ€based regimens compared with 5â€fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients. Cancer, 2012, 118, 3173-3181.	4.1	12
26	Trends in Disparities in Receipt of Adjuvant Therapy for Elderly Stage III Colon Cancer Patients. Medical Care, 2009, 47, 1229-1236.	2.4	30
27	Randomized Phase II Study of Neoadjuvant Combined-Modality Chemoradiation for Distal Rectal Cancer: Radiation Therapy Oncology Group Trial 0012. Journal of Clinical Oncology, 2006, 24, 650-655.	1.6	236
28	A Phase I Trial of TNFerade Biologic in Patients with Soft Tissue Sarcoma in the Extremities. Clinical Cancer Research, 2004, 10, 5747-5753.	7.0	91
29	TNFerade Biologic, an Adenovector With a Radiation-Inducible Promoter, Carrying the Human Tumor Necrosis Factor Alpha Gene: A Phase I Study in Patients With Solid Tumors. Journal of Clinical Oncology, 2004, 22, 592-601.	1.6	198
30	Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. International Journal of Radiation Oncology Biology Physics, 2000, 48, 1075-1080.	0.8	159